Who shouldnt use these peptides: Anyone with active cancer or a recent cancer history (GH and IGF-1 can stimulate growth of some malignancies) Severe uncontrolled diabetes, GH worsens insulin resistance Active proliferative diabetic retinopathy Pregnancy or breastfeeding Children or adolescents (growth plates still open) FDA 503A and what changed for sermorelin compounding This is the part of the conversation most clinic-marketing pages avoid, and it matters enough that you should know it before you start.In late 2023, the FDA reclassified sermorelins bulk substance status, removing it from the 503A compounding pathway that traditional compounding pharmacies operate under
March 13, 2024
Mousavi A, Shojaei S, Soleimani H, Semirani-Nezhad D, Ebrahimi P, Zafari A, et al
The concern is not theoretical: excess GH from any cause, including GH-secreting adenomas in adolescence, is associated with accelerated bone age and, paradoxically, shorter final stature if epiphyses close early [10]
Noom offers a 7-day trial, allowing you to test it out before committing to the monthly fee
